Clinical trials: Smallpox
Neonate, Maternal Transmission
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population…
- Conditions
- Neonate, Maternal Transmission, Mpox, Vaccination
- Trial name
- PregInPoxVac (NCT06844500)
- Testing
- MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)
- Where
- Democratic Republic of the Congo
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Monkeypox (Mpox)
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).
- Trial name
- NCT06549530
- Testing
- MVA-BN
- Where
- 3 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Smallpox
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in…
- Trial name
- NCT00927719
- Testing
- ACAM2000® smallpox vaccine
- Where
- 4 sites in United States
- Volunteers
- 897,227 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults.
- Trial name
- BCV-001 (NCT05935917)
- Testing
- Brincidofovir
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
This is a Phase I/II study evaluating the safety and immunogenicity of LC16m8, a modified vaccinia vaccine. After consent and thorough screening (including safety labs, EKG, and medical history), healthy, previously unvaccinated…
- Trial name
- NCT00103584
- Testing
- LC16m8 Smallpox Vaccine
- Where
- 4 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- VaxGen
Smallpox Vaccine
Immune Responses to Smallpox Vaccination
This study will examine how people s immune systems respond to inoculation with vaccinia virus the standard vaccine used to protect against smallpox and how these responses correlate with symptoms they develop after receiving the…
- Trial name
- NCT00325975
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox, Poxvirus Infection
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
Primary Objective: To estimate the smallpox vaccination take rate in healthy young adults not previously vaccinated with a smallpox vaccine.
- Trial name
- NCT00258947
- Testing
- Smallpox vaccine, LISTER strain, from chick embryo cells
- Where
- 6 sites in France
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Sanofi
Smallpox, Anthrax
VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Our 4-year project uses public domain software and content developed by a University of Alabama at Birmingham (UAB) team and updates, refines, and tailors it to the unique clinician populations and electronic educational…
- Trial name
- NCT00123396
- Testing
- BioCASES and BioTESTS
- Where
- 9 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Smallpox
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
The purpose of this study is to gather information on the safety and the effectiveness of an investigational vaccine for the prevention of smallpox disease.
- Trial name
- NCT00079820
- Testing
- ACAM3000 MVA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Smallpox
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
The primary objective of this study is to evaluate the immune response after a single vaccination of pre-immune subjects compared to two vaccinations in naive subjects.
- Trial name
- NCT00316524
- Testing
- MVA-BN® (IMVAMUNE)
- Where
- Germany
- Volunteers
- 745 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Myocarditis, Pericarditis
ACAM2000® Myopericarditis Registry
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions.
- Trial name
- NCT01395082
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox Vaccine Adverse Reaction
VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Objectives: To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers.
- Trial name
- NCT02443623
- Testing
- Vaccination with ACAM2000
- Where
- Canada
- Volunteers
- 3,032 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
To define the safety of vaccination with APSV as determined by the reactogenicity of the vaccine and the development of expected and un-expected adverse events associated with vaccination.
- Trial name
- NCT00038987
- Testing
- Wetvax (APSV)
- Where
- 4 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Dressing Preparations for Smallpox
The primary purpose of this study is to find out the risk of spreading the vaccine virus, vaccinia, from the smallpox vaccination site when different types of bandages are used to cover the site.
- Trial name
- NCT00063856
- Testing
- Wetvax (APSV)
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox, Atopic Dermatitis
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
- Trial name
- NCT00389103
- Testing
- MVA (smallpox vaccine)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dermatitis, Atopic, Hay Fever
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.
- Trial name
- NCT00189917
- Testing
- IMVAMUNE (MVA-BN)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Vaccinia
SIGA-246 to Treat Smallpox
This study will test an experimental antiviral drug called SIGA-246 for use against the smallpox virus (variola). Although smallpox has been universally eradicated, it could possibly be brought back as a bioweapon.
- Trial name
- NCT00303225
- Testing
- Vaccine: SIGA-246
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
A phase 2 study to assess the MVA smallpox vaccine in previously vaccinated and vaccine- naive subjects at three dose levels.
- Trial name
- NCT00466245
- Testing
- MVA Smallpox vaccine
- Volunteers
- 590 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Smallpox
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
This is a retrospective study of the Department of Defense (DoD) Smallpox Screening Form 600s (SF600s) generated during screening of service members for possible immunization with the ACAM2000® smallpox vaccine.
- Trial name
- NCT01540929
- Where
- United States
- Volunteers
- 5,001 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Smallpox, Mpox
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
- Trial name
- NCT05995275
- Testing
- mRNA-1769
- Where
- 12 sites in United Kingdom
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.